153 related articles for article (PubMed ID: 15579735)
1. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.
Dickinson AJ; Vaidya B; Miller M; Coulthard A; Perros P; Baister E; Andrews CD; Hesse L; Heverhagen JT; Heufelder AE; Kendall-Taylor P
J Clin Endocrinol Metab; 2004 Dec; 89(12):5910-5. PubMed ID: 15579735
[TBL] [Abstract][Full Text] [Related]
2. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
Wémeau JL; Caron P; Beckers A; Rohmer V; Orgiazzi J; Borson-Chazot F; Nocaudie M; Perimenis P; Bisot-Locard S; Bourdeix I; Dejager S
J Clin Endocrinol Metab; 2005 Feb; 90(2):841-8. PubMed ID: 15562016
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.
Stan MN; Garrity JA; Bradley EA; Woog JJ; Bahn MM; Brennan MD; Bryant SC; Achenbach SJ; Bahn RS
J Clin Endocrinol Metab; 2006 Dec; 91(12):4817-24. PubMed ID: 16984988
[TBL] [Abstract][Full Text] [Related]
4. Analysis of peripheral blood T-cell subsets in active thyroid-associated ophthalmopathy: absence of effect of octreotide-LAR on T-cell subsets in patients with thyroid-associated ophthalmopathy.
Vaidya B; Shenton BK; Stamp S; Miller M; Baister E; Andrews CD; Dickinson AJ; Perros P; Kendall-Taylor P
Thyroid; 2005 Sep; 15(9):1073-8. PubMed ID: 16187917
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
6. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
Caroli A; Perico N; Perna A; Antiga L; Brambilla P; Pisani A; Visciano B; Imbriaco M; Messa P; Cerutti R; Dugo M; Cancian L; Buongiorno E; De Pascalis A; Gaspari F; Carrara F; Rubis N; Prandini S; Remuzzi A; Remuzzi G; Ruggenenti P;
Lancet; 2013 Nov; 382(9903):1485-95. PubMed ID: 23972263
[TBL] [Abstract][Full Text] [Related]
7. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
10. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
[TBL] [Abstract][Full Text] [Related]
11. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G;
PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521
[TBL] [Abstract][Full Text] [Related]
12. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
Kung AW; Michon J; Tai KS; Chan FL
Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
[TBL] [Abstract][Full Text] [Related]
13. [Clinical application of orbital scintigraphy with 99Tc(m)-octreotide in patients with thyroid associated ophthalmopathy].
Duan L; Li XF; Lu KY; Zhang CG; Hu G; Liu JZ; Li SJ
Zhonghua Yan Ke Za Zhi; 2006 Dec; 42(12):1068-72. PubMed ID: 17415962
[TBL] [Abstract][Full Text] [Related]
14. Effects of a long-acting formulation of octreotide on renal function and renal sodium handling in cirrhotic patients with portal hypertension: a randomized, double-blind, controlled trial.
Ottesen LH; Aagaard NK; Kiszka-Kanowitz M; Rehling M; Henriksen JH; Pedersen EB; Flyvbjerg A; Bendtsen F
Hepatology; 2001 Sep; 34(3):471-7. PubMed ID: 11526531
[TBL] [Abstract][Full Text] [Related]
15. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma.
Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R
Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
17. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion.
Lustig RH; Greenway F; Velasquez-Mieyer P; Heimburger D; Schumacher D; Smith D; Smith W; Soler N; Warsi G; Berg W; Maloney J; Benedetto J; Zhu W; Hohneker J
Int J Obes (Lond); 2006 Feb; 30(2):331-41. PubMed ID: 16158082
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
